Suppr超能文献

以异源 DNA 初免和病毒样颗粒加强免疫的方式接种疫苗可诱导小鼠产生高效中和抗体应答和保护作用,抵御高致病性 H5N1 流感病毒。

Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus.

机构信息

Unit of Anti-Viral Immunity and Genetic Therapy, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.

出版信息

PLoS One. 2011 Jan 28;6(1):e16563. doi: 10.1371/journal.pone.0016563.

Abstract

BACKGROUND

Although DNA plasmid and virus-like particle (VLP) vaccines have been individually tested against highly pathogenic avian influenza (HPAI) H5N1 viruses, the combination of both vaccines into a heterologous prime-boost strategy against HPAI H5N1 viruses has not been reported before.

METHODOLOGY/PRINCIPAL FINDINGS: We constructed DNA plasmid encoding H5HA (A/Shenzhen/406H/06, subclade 2.3.4) and generated VLP expressing the same H5HA and N1NA. We then compared neutralizing antibody responses and immune protection elicited with heterologous DNA-VLP, homologous DNA-DNA and VLP-VLP prime-boost strategies against HPAI H5N1 viruses in mice. We demonstrate that DNA-VLP elicits the highest neutralizing antibody titers among the three prime-boost strategies, whereas DNA-DNA elicits higher neutralizing antibody titers than VLP-VLP. We show that although all three prime-boost strategies protect mice from death caused by 10 MLD(50) of homologous and heterologous H5N1 challenge, only DNA-VLP and DNA-DNA protect mice from infection as manifested by no weight loss and no lung pathology. In addition, we show that although DNA-VLP and DNA-DNA protect mice from death caused by 1,000 MLD(50) of homologous H5N1 challenge, only DNA-VLP protects mice from infection. Moreover, we show that after 1,000 MLD(50) of heterologous H5N1 challenge, while all mice in PBS, VLP-VLP and DNA-DNA died, 3 of 6 mice in DNA-VLP actually survived. Finally, we show that DNA-VLP completely protects mice from infection after 1,000 MLD(50) of homologous H5N1 challenge even when the challenge was administrated at 60 days post the boost.

CONCLUSIONS/SIGNIFICANCE: These results provide strong support for clinical evaluation of heterologous DNA-VLP prime-boost strategy as a public health intervention against a possible H5N1 pandemic.

摘要

背景

尽管 DNA 质粒和病毒样颗粒(VLP)疫苗已分别针对高致病性禽流感(HPAI)H5N1 病毒进行了测试,但将这两种疫苗组合成针对 HPAI H5N1 病毒的异源初免-加强策略尚未见报道。

方法/主要发现:我们构建了编码 H5HA(A/Shenzhen/406H/06,亚系 2.3.4)的 DNA 质粒,并生成了表达相同 H5HA 和 N1NA 的 VLP。然后,我们比较了异源 DNA-VLP、同源 DNA-DNA 和 VLP-VLP 初免-加强策略在小鼠中针对 HPAI H5N1 病毒产生的中和抗体反应和免疫保护作用。我们证明,在三种初免-加强策略中,DNA-VLP 可诱导最高的中和抗体滴度,而 DNA-DNA 比 VLP-VLP 诱导更高的中和抗体滴度。我们表明,尽管所有三种初免-加强策略都能保护小鼠免受同源和异源 H5N1 10 MLD(50)挑战的致死,但只有 DNA-VLP 和 DNA-DNA 能保护小鼠免受感染,表现为无体重减轻和无肺部病理学。此外,我们表明,尽管 DNA-VLP 和 DNA-DNA 能保护小鼠免受同源 H5N1 1,000 MLD(50)挑战的致死,但只有 DNA-VLP 能保护小鼠免受感染。此外,我们表明,在异源 H5N1 1,000 MLD(50)挑战后,尽管 PBS、VLP-VLP 和 DNA-DNA 组中的所有小鼠都死亡,但在 DNA-VLP 组中有 3 只小鼠实际上存活下来。最后,我们表明,即使在加强后 60 天进行挑战,DNA-VLP 也能完全保护小鼠免受同源 H5N1 1,000 MLD(50)挑战的感染。

结论/意义:这些结果为临床评估异源 DNA-VLP 初免-加强策略作为针对可能的 H5N1 大流行的公共卫生干预措施提供了有力支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c3e/3030595/af8e3d59837a/pone.0016563.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验